Cox-2 inhibitors and the risk of cardiovascular thrombotic events.
CitationCox-2 inhibitors and the risk of cardiovascular thrombotic events. 2012, 105 (4):119-21 Ir Med J
PublisherIrish Medical Journal (IMJ)
JournalIrish medical journal
AbstractIn 1971, Vane showed that the analgesic action of traditional NSAIDs relies on inhibition of the cyclo-oxygenase (COX) enzyme, which in turn results in reduced synthesis of proalgesic prostaglandins. Two decades later COX was shown to exist as two distinct isoforms. The constitutive isoform COX-1, supports the beneficial homeostatic functions whereas the inducible isoform, COX-2 becomes up regulated by inflammatory mediators and its products cause many of the symptoms of inflammatory diseases such as rheumatoid and osteoarthritis. Despite the benefits of NSAIDs for acute and chronic pain one of the most clinically significant and well characterized adverse effect is on GI mucosa. The search for NSAIDs with less gastrointestinal toxicity led to the introduction of the selective cyclo-oxygenase-2 (COX-2) inhibitors. The COX-2 selective (COX-1 sparing) inhibitors are associated with reduced GI mucosal damage as demonstrated in several trials. In light of the overwhelming and sometimes contradictory information for patients and physicians regarding the safety of COX-2 agents this article will summarize the available evidence regarding cardiovascular (CV) safety data and contemporary recommendations for prescribing of COX-2-selective NSAIDs.
- Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
- Authors: Dajani EZ, Islam K
- Issue date: 2008 Aug
- Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
- Authors: Weir MR, Sperling RS, Reicin A, Gertz BJ
- Issue date: 2003 Oct
- Anti-inflammatory drugs in the 21st century.
- Authors: Rainsford KD
- Issue date: 2007
- The use of NSAIDs in rheumatic disorders 2005: a global perspective.
- Authors: Kean WF, Buchanan WW
- Issue date: 2005
- Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
- Authors: Mukherjee D
- Issue date: 2006 Oct